Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DYN · against 307 other Healthcare companies of similar size
Ranked #232 of 308 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score77 peers with a valuation score of 0–9, including DYN · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | DYN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 304 reported | -18.1% | 2.4% | 4% | 30% | |
| EBITDA yieldHigher is better · 302 reported | -19.8% | 4.7% | 3% | 50% | |
| Free cash flow yieldHigher is better · 158 reported | -14.8% | 0.5% | 4% | 20% | |
| Book yieldHigher is better · 302 reported | 23.5% | 28.6% | 41% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 232 | 5.4B USD | 8 | 38 | |
| 232 | 4.8B USD | 8 | 27 | |
| 232 | 3.1B USD | 8 | 27 | |
| 232 | 4.6B USD | 8 | 29 | |
| 232 | 3.4B USD | 8 | 35 | |
| 232 | 3.3B USD | 8 | 44 | |
| 232 | 5.1B USD | 8 | 35 | |
| 232 | 1.8B USD | 8 | 31 | |
| 232 | 4.1B USD | 8 | 42 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score